Exor Ventures

Tracked participation in 2 Atlas companies, with 2 explicitly attributed leads.

2portfolio companies

3round participations

2lead positions

$100Mled round total

Conviction

Most recent leads

The latest rounds this investor is sourced as leading, newest first.

Jun 2024Iambic TherapeuticsSeries B extension (oversubscribed)$50MJun 2023Iambic TherapeuticsSeries B Extension$50M

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic Therapeutics—Jun 2023 → Jun 20242 rounds2 led—

MAMistral AI$260MJun 2023 → Jun 20231 roundParticipant—

DateCompanyRoundRaisedValuationRoleEvidence

Jun 18, 2024ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsSeries B extension (oversubscribed)$50M—Lead

Source ↗

Jun 18, 2023ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsSeries B Extension$50M—Lead

Source ↗

Jun 13, 2023MAMistral AISeed$113M$260MParticipant

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Jun 13, 2023MAMistral AISeed$113M$260MParticipant

Source ↗